Bausch + Lomb Corporation (BLCO)

USD 18.24

(-3.24%)

EBITDA Summary of Bausch + Lomb Corporation

  • Bausch + Lomb Corporation's latest annual EBITDA in 2023 was 586 Million USD , up 31.51% from previous year.
  • Bausch + Lomb Corporation's latest quarterly EBITDA in 2024 Q3 was 43 Million USD , up 11.76% from previous quarter.
  • Bausch + Lomb Corporation reported an annual EBITDA of 599 Million USD in 2022, down -41.78% from previous year.
  • Bausch + Lomb Corporation reported an annual EBITDA of 762 Million USD in 2021, up 4.67% from previous year.
  • Bausch + Lomb Corporation reported a quarterly EBITDA of 125 Million USD for 2024 Q1, down -30.17% from previous quarter.
  • Bausch + Lomb Corporation reported a quarterly EBITDA of 150 Million USD for 2024 Q2, up 8.8% from previous quarter.

Annual EBITDA Chart of Bausch + Lomb Corporation (2023 - 2018)

Historical Annual EBITDA of Bausch + Lomb Corporation (2023 - 2018)

Year EBITDA EBITDA Growth
2023 586 Million USD 31.51%
2022 599 Million USD -41.78%
2021 762 Million USD 4.67%
2020 739 Million USD -25.07%
2019 936 Million USD 7.4%
2018 922 Million USD 0.0%

Peer EBITDA Comparison of Bausch + Lomb Corporation

Name EBITDA EBITDA Difference
Alcon Inc. 2.39 Billion USD 75.512%
AptarGroup, Inc. 663.83 Million USD 11.725%
Baxter International Inc. 2.77 Billion USD 78.89%
Becton, Dickinson and Company 2.42 Billion USD 75.835%
Haemonetics Corporation 262.09 Million USD -123.58%
Envista Holdings Corp 171.1 Million USD -242.49%
ResMed Inc. 1.6 Billion USD 63.383%
Teleflex Incorporated 792.26 Million USD 26.034%
Warby Parker Inc. -30.21 Million USD 2039.627%
West Pharmaceutical Services, Inc. 847.8 Million USD 30.88%